ReviewCurrent pain and headache reports2026
Playing by the Rules: A Review of the Modern Regulatory Framework for Regenerative Medicine.
Review in Current pain and headache reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review provides the reader with an up-to-date summary of the U.S. regulatory framework as it relates to regenerative medicine therapies used in pain management. This includes relevant historical background, legal discussion, prevailing evidence for the discussed therapies, and expert opinion on potential pathways forward that promote safety alongside innovation. RECENT
findingsRecent evidence in the regenerative medicine space supports the use of platelet rich plasma (PRP) for knee osteoarthritis, although findings are not uniform, with more limited data for bone marrow aspirate concentrate (BMAC) and adipose-derived products such as stromal vascular fraction (SVF). Perinatal tissue and exosomes show potential with early preclinical work. We gain valuable insight from warning notices and court rulings into how the FDA interprets guidance surrounding these therapies. With continued use and commercialization of regenerative medicine products for pain management, it is important to understand the regulatory aspects of these different therapies and how it may impact the day to day.
Indexed as
Identifiers
42696062What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.